SOURCE-LINKED STUDY SUMMARY
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Abstract summarizedQuality not appraised
- What was studied
- A randomized, blinded trial compared retatrutide with placebo for weight loss over 48 weeks.
- Who / model studied
- 338 adults with obesity, or overweight plus a weight-related condition, participated.
- Studied dose & schedule
- In this 48-week, placebo-controlled phase 2 trial, adults were assigned subcutaneous retatrutide once weekly at target doses of 1, 4, 8, or 12 mg, or placebo. The 4-mg groups began at 2 or 4 mg; the 8-mg groups at 2 or 4 mg; the 12-mg group at 2 mg. These are studied arms, not personal dosing advice.
- What the study found
- At 48 weeks, average weight loss was 24.2% in the highest-dose group versus 2.1% with placebo.
- Limitations & context
- Digestive side effects were common and dose-related. Heart rate also increased with dose. These findings describe this trial's population and follow-up.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2301972